chart update, page-117

POH is business as usual. Newsletter is coming soon according to POHs Investor Relations Manager and the company programs are rapidly advancing in line with the reset schedules ann in the last Pain Announcement. Morale at POH HQ is I imagine at an all time high- as POH is now humming with multiple projects entering Phase 2 trials...and the company is now at last within reach of some of its key commercial goals. Keep in mind POH has not conducted a Phase 2 since its 2b Insulin trial- a very long time ago!

So what else do we need?

POH must make board changes, appoint a well credentialed new CEO ( to allow Harry Rosen's return to the US where he is needed at the Pharma coalface); and...wait for it...POH must publish its science in peer reviewed publications to remove any doubt that Esra has in some way guilded the lily or compromised the science in pursuit of her theft of co funds . Up until circa 2007 POH was prolific in its peer review publishing and then stopped- no idea why but perhaps was no longer a priority- the POH clinic was very busy from this time - so its time to update the scientific community and Pharma CSOs while placating investor angst about TPM being the real deal. Personally Ive no concerns as Novartis and numerous independant clinical trials have validated TPM. We also now have anecdotal evidence from Equine Feeds and Supplements that TPM is delivering in the real world.

Esra's departure will in time be viewed as the making of POH. Meanwhile POH is doing everything Id expect of it to recover from this event and get its programs back on track. Keep the faith.